Immune and inflammatory responses in GERD and lansoprazole

Journal of Clinical Biochemistry and Nutrition

Volumn 41, Issue 2, 2007, Pages 84-91

  Isomoto, Hajime ^a   Nishi, Yoshito ^a   Kanazawa, Yusei ^a   Shikuwa, Saburo ^a   Mizuta, Yohei ^a   Inoue, Kenichiro ^b   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Shunkaikai Inoue Hospital   (Japan)

Author keywords

Barrett's esophagus; GERD; IL 8; Proinflammatory cytokine; Reflux esophagitis

Indexed keywords

BETA CHEMOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; LANSOPRAZOLE; MACROPHAGE CHEMOTACTIC FACTOR;

BARRETT ESOPHAGUS; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HUMAN; HYPERPLASIA; IMMUNE RESPONSE; INFLAMMATION; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; T LYMPHOCYTE; TH2 CELL; TREATMENT RESPONSE;

EID: 34948862089     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.2007012     Document Type: Review

References (60)

1. Odze, R.D.: Pathology of the gastroesophageal junction. Semin. Diagn. Pathol., 22, 256-265, 2005.
2. Moayyedi, P. and Talley, N.J.: Gastro-oesophageal reflux disease. Lancet, 367, 2086-2100, 2006.
3. Cheng, L., Harnett, K.M., Cao, W., Liu, F., Behar, J., Fiocchi, C., and Biancani, P.: Hydrogen peroxide reduces lower esophageal sphincter tone in human esophagitis. Gastroenterology, 129, 1675-1685, 2005.
4. Dent, J., Holloway, R.H., Toouli, J., and Dodds, W.J.: Mechanisms of lower oesophageal sphincter incompetence in patients with symptomatic gastrooesophageal reflux. Gut, 29, 1020-1028, 1988.
5. Heading, R.: Epidemiology of oesophageal reflux disease. Scand. J. Gastroenterol., 24, 25-36, 1989.
6. rd., Johnson, D.A., Cruess, D.F., Cotelingam, J.D., and Gurney, M.S.: Barrett's esophagus: A prevalent occult complication of gastro-esophageal reflux disease. Gastroenterology, 92, 118-124, 1987.
7. Spechler, S.J., Zeroogian, J.M., Antonioli, D.A., Wang, H.H., and Goyal, R.K.: Prevalence of metaplasia at the gastro-oesophageal junction. Lancet, 344, 1533-1536, 1994.
8. Cameron, A., Kamath, P., and Carpenter, H.: Prevalence of Barrett's esophagus and intestinal metaplasia at the esophagogastric junction. Gastroenterology, 112, A82, 1997.
9. Hirschowitz, B.I.: Gastric acid and pepsin secretion in patients with Barrett's esophagus and appropriate controls. Dig. Dis. Sci., 41, 1384-1391, 1996.
10. Liron, R., Parrilla, P., Martinez de Haro, L.F., Ortiz, A., Robles, R., Lujan, J.A., Fuente, T., and Andres, B.: Quantification of duodenogastric reflux in Barrett's esophagus. Am. J. Gastroenteol., 92, 32-36, 1997.
11. Avidan, B., Sonnenberg, A., and Schnell, T.: Acid reflux is a poor predictor of esophageal mucosal injury. Gastroenterology, 118, A2584, 2000.
12. Lanas, A., Royo, Y., Ortego, J., Molina, M., and Sainz, R.: Experimental esophagitis induced by acid and pepsin in rabbits mimicking human reflux esophagitis. Gastroenterology, 116, 97-107, 1999.
13. Jimenez, P., Piazuelo, E., Sanchez, M.T., Ortego, J., Soteras, F., and Lanas, A.: Free radicals and antioxidant systems in reflux esophagitis and Barrett's esophagus. World J. Gastroenterol., 11, 2697-2703, 2005.
14. Oh, T.Y., Lee, J.S., Ahn, B.O., Cho, H., Kim, W.B., Kim, Y.B., Surh, Y.J., Cho, S.W., and Hahm, K.B.: Oxidative damages are critical in pathogenesis of reflux esophagitis: implication of antioxidants in its treatment. Free Radic. Biol. Med., 30, 905-915, 2001.
15. Fitzgerald, R.C., Onwuegbusi, B.A., Bajaj-Elliott, M., Saeed, I.T., Burnham, W.R., and Farthing, M.J.: Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut, 50, 451-459, 2002.
16. Isomoto, H., Wang, A., Mizuta, Y., Akazawa, Y., Ohba, K., Omagari, K., Miyazaki, M., Murase, K., Hayashi, T., Inoue, K., Murata, I., and Kohno, S.: Elevated levels of chemokines in esophageal mucosa of patients with reflux esophagitis. Am. J. Gastroenterol., 98, 551-556, 2003.
17. Isomoto, H., Nishi, Y., Wang, A., Takeshima, F., Omagari, K., Mizuta, Y., Shikuwa, S., Murata, I., and Kohno, S.: Mucosal concentrations of proinflammatory cytokines and chemokines at gastric cardia: implication of Helicobacter pylori infection and gastroesophageal reflux. Am. J. Gastroenterol., 99, 1063-1068, 2004.
18. Fitzgerald, R.C., Abdalla, S., Onwuegbusi, B.A., Sirieix, P., Saeed, I.T., Burnham, W.R., and Farthing, M.J.: Inflammatory gradient in Barrett's oesophagus: implications for disease complications. Gut, 51, 316-322, 2002.
19. Yoshida, N., Uchiyama, K., Kuroda, M., Sakuma, K., Kokura, S., Ichikawa, H., Naito, Y., Takemura, T., Yoshikawa, T., and Okanoue, T.: Interleukin-8 expression in the esophageal mucosa of patients with gastroesophageal reflux disease. Scand. J. Gastroenterol., 39, 816-822, 2004.
20. Baggiolini, M., Loetscher, P., and Moser, B.: Interleukin-8 and the chemokine family. Int. J. Immunopharmacol., 17, 103-108, 1995.
21. Mukaida, N., Harada, A., and Matsushima, K.: Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions. Cytokine Growth Factor Rev., 9, 9-23, 1998.
22. Isomoto, H., Mizuta, Y., Miyazaki, M., Takeshima, F., Omagari, K., Murase, K., Nishiyama, T., Inoue, K., Murata, I., and Kohno, S.: Implication of NF-kappaB in Helicobacter pylori-associated gastritis. Am. J. Gastroenterol., 95, 2768-2776, 2000.
23. Kanazawa, Y., Isomoto, H., Wen, C.Y., Wang, A.P., Saenko, V.A., Ohtsuru, A., Takeshima, F., Omagari, K., Mizuta, Y., Murata, I., Yamashita, S., and Kohno, S.: Impact of endoscopically minimal involvement on IL-8 mRNA expression in esophageal mucosa of patients with non-erosive reflux disease. World J. Gastroenterol., 9, 2801-2804, 2003.
24. Hoshihara, Y.: Endoscopic findings of GERD. Nippon Rinsho, 62, 1459-1464, 2004.
25. Isomoto, H., Inoue, K., and Kohno, S.: Interleukin-8 levels in esophageal mucosa and long-term clinical outcome of patients with reflux esophagitis. Scand. J. Gastroenterol., 43, 410-1, 2007.
26. Thompson, M.D., Takasaki, J., Capra, V., Rovati, G.E., Siminovitch, K.A., Burnham, W.M., Hudson, T.J., Bosse, Y., and Cole, D.E.: G-protein-coupled receptors and asthma endophenotypes: the cysteinyl leukotriene system in perspective. Mol. Diagn. Ther., 10, 353-366, 2006.
27. Mukaida, N.: Interleukin-8: An expanding universe beyond neutrophil Chemotaxis and activation. Int. J. Hematol., 72, 391-398, 2000.
28. Isomoto, H., Nishi, Y., and Kohno, S.: CXC receptor 1 is overexpressed in endoscopy-negative gastroesophageal reflux disease. Scand. J. Gastroenterol., 40, 231-232, 2005.
29. Ismail-Beigi, F., Horton, R.F., and Pope, C.E. 2nd.: Histological consequences of gastroesophageal reflux in man. Gastroenterology, 58, 163-174, 1970.
30. Baggiolini, M., Dewald, B., and Moser, B.: Human chemokines: An update. Annu. Rev. Immunol., 15, 675-705, 1997.
31. Schumacher, C., Clark-Lewis, I., Baggiolini, M., and Moser, B.: High- and low-affinity binding of GRO alpha and neutrophil-activating peptide 2 to interleukin 8 receptors on human neutrophils. Proc. Natl. Acad. Sci. USA., 89, 10542-10546, 1992.
32. Dumont, R.A., Car, B.D., Voitenok, N.N., Junker, U., Moser, B., Zak, O., and O'Reilly, T.: Systemic neutralization of interleukin-8 markedly reduces neutrophilic pleocytosis during experimental lipopolysaccharide-induced meningitis in rabbits. Infect. Immun., 68, 5756-5763, 2000.
33. Suzuki, S., Kobayashi, M., Chiba, K., Horiuchi, I., Wang, J., Kondoh, T., Hashino, S., Tanaka, J., Hosokawa, M., and Asaka, M.: Autocrine production of epithelial cell-derived neutrophil attractant-78 induced by granulocyte colony-stimulating factor in neutrophils. Blood, 99, 1863-1865, 2002.
34. Browning, D.D., Diehl, W.C., Hsu, M.H., Schraufstatter, I.U., and Ye, R.D.: Autocrine regulation of interleukin-8 production in human monocytes. Am. J. Physiol. Lung. Cell Mol. Physiol., 279, L1129-L1136, 2000.
35. Venkatakrishnan, G., Salgia, R., and Groopman, J.E.: Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J. Biol. Chem., 275, 6868-6875, 2000.
36. Chuntharapai, A. and Kim, K.J.: Regulation of the expression of IL-8 receptor A/B by IL-8: Possible functions of each receptor. J. Immunol., 155, 2587-2594, 1995.
37. Yoshida, N.: Inflammation and oxidative stress in gastroesophageal reflux disease. J. Clin. Biochem. Nutr., 40, 13-23, 2007.
38. Baggiolini, M., Loetscher, P., and Moser, B.: Interleukin-8 and the chemokine family. Int. J. Immunopharmacol., 17, 103-108, 1995.
39. Mukaida, N., Harada, A., Yasumoto, K., and Matsushima, K.: Properties of pro-inflammatory cell type-specific leukocyte chemotactic cytokines, interleukin 8 (IL-8) and monocyte chemotactic and activating factor (MCAF). Microbiol. Immunol., 36, 773-789, 1992.
40. Kobayashi, S. and Kasugai, T.: Endoscopic and biopsy criteria for the diagnosis of esophagitis with a fiberoptic esophagoscope. Am. J. Dig. Dis., 19, 345-352, 1974.
41. Frierson, H.F. Jr.: Histology in the diagnosis of reflux esophagitis. Gastroenterol. Clin. North Am., 19, 631-644, 1990.
42. Karin, M.: Nuclear factor-kappaB in cancer development and progression. Nature, 441, 431-436, 2006.
43. Baeuerle, P.A. and Baltimore, D.: NF-κB: Ten years after. Cell, 87, 13-20, 1996.
44. Isomoto, H., Miyazaki, M., Mizuta, Y., Takeshima, F., Murase, K., Inoue, K., Yamasaki, K., Murata, I., Koji, T., and Kohno, S.: Expression of nuclear factor-kappaB in Helicobacter pylori-infected gastric mucosa detected with southwestern histochemistry. Scand. J. Gastroenterol., 35, 247-254, 2000.
45. Tselepis, C., Perry, I., Dawson, C., Hardy, R., Darnton, S.J., McConkey, C., Stuart, R.C., Wright, N., Harrison, R., and Jankowski, J.A.: Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene, 21, 6071-6081, 2002.
46. Moons, L.M., Kusters, J.G., Bultman, E., Kuipers, E.J., van Dekken, H., Tra, W.M., Kleinjan, A., Kwekkeboom, J., van Vliet, A.H., and Siersema, P.D.: Barrett's oesophagus is characterized by a predominantly humoral inflammatory response. J. Pathol., 207, 269-276, 2005.
47. Hirano, T.: Interleukin 6 and its receptor: ten years later. Int. Rev. Immunol., 16, 249-284, 1998.
48. Dvorakova, K., Payne, C.M., Ramsey, L., Holubec, H., Sampliner, R., Dominguez, J., Dvorak, B., Bernstein, H., Bernstein, C., Prasad, A., Fass, R., Cui, H., and Garewal, H.: Increased expression and secretion of interleukin-6 in patients with Barrett's esophagus. Clin. Cancer. Res., 10, 2020-2028, 2004.
49. Shibata, F.: The role of rat cytokine-induced neutrophil chemoattractants (CINCs) in inflammation. Yakugaku Zasshi, 122, 263-268, 2002.
50. Hayakawa, T., Fujiwara, Y., Hamaguchi, M., Sugawa, T., Okuyama, M., Sasaki, E., Watanabe, T., Tominaga, K., Oshitani, N., Higuchi, K., and Arakawa, T.: Roles of cyclooxygenase 2 and microsomal prostaglandin E synthase 1 in rat acid reflux oesophagitis. Gut, 55, 450-456, 2006.
51. Oh, T.Y., Lee, J.S., Ahn, B.O., Cho, H., Kim, W.B., Kim, Y.B., Surh, Y.J., Cho, S.W., Lee, K.M., and Hahm, K.B.: Oxidative stress is more important than acid in the pathogenesis of reflux oesophagitis in rats. Gut, 49, 364-371, 2001.
52. Naito, Y., Kuroda, M., Uchiyama, K., Mizushima, K., Akagiri, S., Takagi, T., Handa, O., Kokura, S., Yoshida, N., Ichikawa, H., and Yoshikawa, T.: Inflammatory response of esophageal epithelium in combined-type esophagitis in rats: a transcriptome analysis., Int. J. Mol. Med., 18, 821-828, 2006.
53. Jenkins, G.J., Harries, K., Doak, S.H., Wilmes, A., Griffiths, A.P., Baxter, J.N., and Parry, J.M.: The bile acid deoxycholic acid (DCA) at neutral pH activates NF-kappaB and induces IL-8 expression in oesophageal cells in vitro. Carcinogenesis, 25, 317-323, 2004.
54. Capodicasa, E., De Bellis, F., and Pelli, M.A.: Effect of lansoprazole on human leukocyte function. Immunopharmacol. Immunotoxicol., 21, 357-377, 1999.
55. Becker, J.C., Grosser, N., Waltke, C., Schulz, S., Erdmann, K., Domschke, W., Schroder, H., and Pohle, T.: Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells. Biochem. Biophys. Res. Commun., 345, 1014-1021, 2006.
56. Hinoki, A., Yoshimura, K., Fujita, K., Akita, M., Ikeda, R., Nagashima, M., Nomura, M., and Satomi, A.: Suppression of proinflammatory cytokine production in macrophages by lansoprazole. Pediatr. Surg. Int., 22, 915-923, 2006.
57. Stocker, R. and Perrella, M.A.: Heme oxygenase-1: a novel drug target for atherosclerotic diseases? Circulation, 114, 2178-2189, 2006.
58. Farombi, E.O. and Surh, Y.J.: Heme oxygenase-1 as a potential therapeutic target for hepatoprotection. J. Biochem. Mol. Biol., 39, 479-491, 2006.
59. Becker, J.C., Domschke, W., and Pohle, T.: Current approaches to prevent NSAJD-induced gastropathy - COX selectivity and beyond. Br. J. Clin. Pharmacol., 58, 587-600, 2004.
60. Yeo, M., Kim, D.K., Chung, I.S., Moon, B.S., Song, K.S., and Hahm, K.B.: The novel acid antagonists for antisecretory actions with their peculiar applications beyond acid suppression. J. Clin. Biochem. Nutr., 38, 1-8, 2006.